Fig. 1.

EGFR copy number status and outcome following treatment with platinum-based chemotherapy in gastroesophageal cancers. a Advanced stage patients (n = 52) treated with palliative platinum-based combination chemotherapy categorised as EGFR amplified and EGFR non-amplified. b Advanced stage patients treated with palliative platinum-based combination chemotherapy categorised as EGFR amplified, EGFR high polysomy or EGFR copy number gain negative (CNG negative includes EGFR disomy, low trisomy, high trisomy and low polysomy). c Operable gastroesophageal cancers treated with surgical resection alone or platinum-based neo-adjuvant chemotherapy (NACT) followed by surgical resection categorised as EGFR copy number gain positive (CNG positive, includes EGFR amplification and high polysomy), or EGFR CNG negative